IMMUNIC, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$103.2M | -$98.1M | -$99.2M | -$119.5M | -$91.7M |
| Operating expenses | $103.2M | $98.1M | $99.2M | $119.5M | $91.7M |
| Cash from operations | -$85.8M | -$84.8M | -$70.8M | -$65.1M | -$83.2M |
| Capital expenditure | $161,000 | $264,000 | $334,000 | $112,000 | $67,000 |
| Free cash flow | -$86.0M | -$85.0M | -$71.2M | -$65.3M | -$83.3M |
| Impairments | $0 | $0 | $0 | $33.0M | $0 |
| Total assets | $24.1M | $40.9M | $54.3M | $127.8M | $139.1M |
| Total liabilities | $30.7M | $22.4M | $25.4M | $14.1M | $12.0M |
Shares outstanding 13.6M · Free float 22.6%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.